Market
Outcome of first UK clinical trial on puberty blockers for under-18s by end of 2026
2
Resolution / Starting Odds
Positive outcome • 25%
Negative outcome • 25%
Inconclusive • 25%
Trial not completed • 25%
Publication of trial results in medical journals or official NHS reports
Story
UK Indefinitely Bans Puberty Blockers for Under-18s After Expert Safety Warning
Dec 11, 2024, 03:27 PM
The UK government has announced an indefinite ban on the prescription of puberty blockers for minors under the age of 18 with gender dysphoria. The decision follows expert advice warning of an "unacceptable safety risk" associated with the use of these medications in children. The Department of Health and Social Care stated that emergency measures, first introduced in May 2024 after the Cass Review highlighted insufficient evidence of safety, will be made permanent. Puberty blockers will now only be available to under-18s through approved clinical trials, with the NHS poised to announce the protocol for these trials. Health Secretary Wes Streeting said that the government is working with NHS England to implement holistic support for patients and their families.
View original story
Similar markets
Inconclusive outcome • 25%
Negative outcome • 25%
Positive outcome • 25%
Trials not completed • 25%
Trial not completed • 25%
Safe and effective • 25%
Unsafe • 25%
Inconclusive • 25%
Proven unsafe • 25%
Proven safe and effective • 25%
Proven ineffective • 25%
Inconclusive results • 25%
Yes • 50%
No • 50%
Inconclusive Results • 25%
Found Not Safe • 25%
Found Safe but Not Effective • 25%
Found Safe and Effective • 25%
Ban is lifted • 25%
Ban remains unchanged • 25%
Ban is modified • 25%
New restrictions added • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%